Noritate

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 4/20/2022
Drug Description

What is Noritate and how is it used?

Noritate is a prescription medicine used to treat the symptoms of Rosacea. Noritate may be used alone or with other medications.

Noritate belongs to a class of drugs called Antibacterials, Topical.

It is not known if Noritate is safe and effective in children.

What are the possible side effects of Noritate?

Noritate may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat, and
  • severe stinging or burning after applying the medication

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Noritate include:

  • mild burning or stinging,
  • numbness or tingly feeling in your hands or feet,
  • mild skin redness or irritation,
  • dry, scaly, or itchy skin,
  • nausea, and
  • metallic taste in your mouth

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Noritate. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

FOR TOPICAL USE ONLY (NOT FOR OPHTHALMIC USE)

DESCRIPTION

NORITATE™ (metronidazole cream) Cream, 1%, contains metronidazole, USP. Chemically, metronidazole is 2-methyl-5-nitro-1H-imidazole-1-ethanol.

The molecular formula for metronidazole is C6H9N3O3.

Metronidazole has a molecular weight of 171.16. It is a white to pale yellow crystalline powder. It is slightly soluble in alcohol and has a solubility in water of 10 mg/mL at 20°C. Metronidazole is a member of the imidazole class of anti-bacterial agents and is classified as an antiprotozoal and anti-bacterial agent.

NORITATE (metronidazole) is an emollient cream; each gram contains 10 mg micronized metronidazole USP, in a base of purified water USP, stearic acid NF, glyceryl monostearate NF, glycerin USP, methylparaben NF, trolamine NF and propylparaben NF.

Indications & Dosage

3 pharmacies near 20147 have coupons for MetroCream (Brand Names:Noritate for 60GM of 1%)

Harris Teeter Pharmacy
Harris Teeter Pharmacy
$378.07

Est. Regular Price

$148.97

with free coupon

View Coupon
CVS Pharmacy
CVS Pharmacy
$378.07

Est. Regular Price

$151.76

with free coupon

View Coupon
Walgreens
Walgreens
$378.07

Est. Regular Price

$152.8

with free coupon

View Coupon

INDICATIONS

Noritate is indicated for the topical treatment of inflammatory lesions and erythema of rosacea.

DOSAGE AND ADMINISTRATION

Areas to be treated should be cleansed before application of Noritate. Apply and rub in a thin film of Noritate once daily to entire affected area(s). Patients may use cosmetics after application of Noritate.

HOW SUPPLIED

Cream - 60 g aluminum tube - NDC 0187-5202-60.

Keep out of reach of children.

Storage

Store at controlled room temperature 20° to 25°C (68° to 77°F).

Manufactured by: Bausch Health Companies Inc. Laval, Quebec H7L 4A8, Canada. Revised Jun 2020.

QUESTION

Rosacea usually first appears on the ________. See Answer
Side Effects & Drug Interactions

SIDE EFFECTS

Safety data from 302 patients who used Noritate (n=200) or vehicle control (n=102) once daily in clinical trials and experienced an adverse event considered to be treatment related include: application site reaction (Noritate 1, vehicle 1), condition aggravated (Noritate 1, vehicle 0), paresthesia (Noritate 0, vehicle 1), acne (Noritate 1, vehicle 0), dry skin (Noritate 0, vehicle 2). The majority of adverse reactions were mild to moderate in severity.

Two patients treated with Noritate once daily discontinued treatment because of adverse events: one for a severe flare of comedonal acne and one for rosacea aggravated.

Additional clinical adverse effects reported spontaneously since the drug was marketed are uncommon and include tingling or numbness of extremities, allergic reactions, skin and eye irritation, rash, headache, nausea and dry mouth.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when Noritate is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption. (See CLINICAL PHARMACOLOGY and Pharmacokinetics)

Warnings & Precautions

WARNINGS

No Information Provided

PRECAUTIONS

General

If a reaction suggesting local skin irritation occurs, patients should be directed to discontinue use of the medication. Conjunctivitis associated with topical use of metronidazole on the face has been reported. Contact with the eyes should be avoided. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of, blood dyscrasia.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

In several long-term studies in mice, oral doses of approximately 225 mg/m2/day or greater (approximately 37 times the human topical dose on a mg/m2 basis) were associated with an increase in pulmonary tumors and lymphomas. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses >885 mg/m2/day (144 times the topical human dose).

Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohn’s disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohn’s disease treated with the drug for 8 months.

In one published study, using albino hairless mice, intraperitoneal administration of metronidazole at a dose of 45 mg/m2/day (approximately 7 times the human topical dose on a mg/m2 basis) was associated with an increase in ultraviolet radiation-induced skin carcinogenesis. Neither dermal carcinogenicity nor photocarcinogenicity studies have been performed with Noritate or any marketed metronidazole formulations.

Pregnancy

Teratogenic Effects

There are no adequate and well-controlled studies with the use of Noritate in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of metronidazole to rats or mice at 200 and 20 times, respectively, the expected clinical dose. However, oral metronidazole has shown carcinogenic activity in rodents. Because animal reproduction studies are not always predictive of human response, Noritate should be used during pregnancy only if clearly needed.

Nursing Mothers

After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels taken after topical metronidazole application are significantly lower than those achieved after oral metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the risk to the infant.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Overdose & Contraindications

OVERDOSE

No specific information available.

CONTRAINDICATIONS

NORITATE (metronidazole) is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation.

 

Clinical Pharmacology

CLINICAL PHARMACOLOGY

Pharmacokinetics

When a one gram dose of Noritate Cream, 1%, was applied in a single application to the face of 16 healthy volunteers, low concentrations of metronidazole were detected in the plasma of 7 of the volunteers. The mean±SD Cmax of metronidazole was 27.6±7.3 ng/mL, which is about 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (Tmax) in the volunteers with detectable metronidazole was 8-12 hours after topical application.

Pharmacodynamics

The mechanisms by which metronidazole acts in reducing inflammatory lesions of rosacea are unknown.

Clinical Studies

Safety and efficacy of Noritate were evaluated in two randomized vehicle-controlled clinical studies for the treatment of rosacea, which excluded patients who had nodules, moderate or severe rhinophyma, dense telangiectases, plaque-like facial edema or ocular involvement and those who had a history of not responding to metronidazole therapy for rosacea. Of the patients included in the efficacy database (n=416), there were 142 men and 274 women. Endpoint efficacy data comparisons for patients treated with daily Noritate or vehicle applications are listed below.

Inflammatory Lesion Counts and Erythema Severity Scores in Two Clinical Trials for Rosacea

Noritate Vehicle
Study 1 Study 2 Study 1 Study 2
N Result N Result N Result N Result
Papules + Pustules Count
Baseline 89 15 92 19 50 18 49 17
Week 10 80 7* 82 8 45 15 41 12
  Reduction 49%* 58%* 17% 30%
Papules Count
Baseline 89 13 92 17 50 15 49 15
Week 10 80 7* 82 7 45 12 41 11
  Reduction 41%* 55%* 14% 28%
Erythema Score
Baseline 89 2.2 92 2.3 50 2.2 49 2.2
Week 10 80 1.3* 82 1.4* 45 1.7 41 1.8
  Reduction 42%* 40%* 25% 19%
*Statistically significant differences between Noritate and vehicle groups with p≤0.05. Erythema scores: 0=none, 1=mild, 2=moderate and 3=severe.

Safety Studies

Studies of contact sensitization (n=258), phototoxicity (n=21), and photocontact sensitization (n=29) of Noritate were conducted. No evidence of sensitization or phototoxicity was seen in these studies.

Medication Guide

PATIENT INFORMATION

Patients using Noritate should receive the following information and instructions:

  1. This medication is to be used as directed.
  2. It is for external use only.
  3. Avoid contact with the eyes.
  4. Cleanse affected area(s) before applying Noritate.
  5. This medication should not be used for any disorder other than that for which it is prescribed.
  6. Patients should report any adverse reaction to their physician.
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors